|1 Table of Contents 3
|1.1 List of Tables 6
|1.2 List of Figures 6
2 Introduction 8
2.1 What Is This Report About? 8
2.2 Drug Delivery Devices Market Segmentation 8
2.3 Definitions of Markets Covered in the Report 9
3 Drug Delivery Devices Market, Australia 11
3.1 Drug Delivery Devices Market, Australia, Revenue ($m), 2018-2033 11
3.2 Drug Delivery Devices Market, Australia, Revenue Mix ($m), 2023 12
3.3 Drug Delivery Devices Market, Australia, Category Contribution by Revenue ($m), 2023 13
3.4 Drug Delivery Devices Market, Australia, Revenue ($m), 2018-2033 14
3.5 Drug Delivery Devices Market, Australia, Volume (Units), 2018-2033 16
3.6 Drug Delivery Devices Market, Australia, Volume (Units), 2018-2033 17
3.7 Drug Delivery Devices Market, Australia, Company Share by Revenue ($m), 2023 19
4 Central Venous Catheters Market, Australia 21
4.1 Central Venous Catheters Market, Australia, Revenue Mix ($m), 2023 21
4.2 Central Venous Catheters Market, Australia, Segment Contribution (%), 2023 22
4.3 Central Venous Catheters Market, Australia, Revenue ($m), 2018-2033 23
4.4 Central Venous Catheters Market, Australia, Volume (Units), 2018-2033 25
4.5 Central Venous Catheters Market, Australia, Average Price ($) , 2018-2033 27
4.6 Central Venous Catheters Market, Australia, Distribution Share by Revenue ($m), 2023 28
4.7 Central Venous Catheters Market, Australia, Company Share by Revenue ($m), 2023 29
5 Implantable Ports Market, Australia 31
5.1 Implantable Ports Market, Australia, Revenue Mix ($m), 2023 31
5.2 Implantable Ports Market, Australia, Segment Contribution (%), 2023 32
5.3 Implantable Ports Market, Australia, Revenue ($m), 2018-2033 33
5.4 Implantable Ports Market, Australia, Volume (Units), 2018-2033 35
5.5 Implantable Ports Market, Australia, Average Price ($) , 2018-2033 37
5.6 Implantable Ports Market, Australia, Distribution Share by Revenue ($m), 2023 38
5.7 Implantable Ports Market, Australia, Company Share by Revenue ($m), 2023 39
6 Infusion Systems Market, Australia 40
6.1 Infusion Systems Market, Australia, Revenue Mix ($m), 2023 40
6.2 Infusion Systems Market, Australia, Segment Contribution (%), 2023 41
6.3 Infusion Systems Market, Australia, Revenue ($m), 2018-2033 42
6.3.1 Infusion Pump Disposables Market, Australia, Revenue ($m), by Segment, 2018-2033 44
6.3.2 Infusion Pumps Market, Australia, Revenue ($m), by Segment, 2018-2033 46
6.4 Infusion Systems Market, Australia, Volume (Units), 2018-2033 47
6.4.1 Infusion Pump Disposables Market, Australia, Volume (Units), by Segment, 2018-2033 49
6.4.2 Infusion Pumps Market, Australia, Volume (Units), by Segment, 2018-2033 51
6.5 Infusion Systems Market, Australia, Average Price ($) , 2018-2033 53
6.6 Infusion Systems Market, Australia, Distribution Share by Revenue ($m), 2023 54
6.7 Infusion Systems Market, Australia, Company Share by Revenue ($m), 2023 55
7 Overview of Key Companies in Australia, Drug Delivery Devices Market 56
7.1 B. Braun Melsungen AG 56
7.1.1 Company Overview 56
7.2 Becton Dickinson and Co 56
7.2.1 Company Overview 56
7.3 Teleflex Inc 56
7.3.1 Company Overview 56
7.4 AngioDynamics Inc 56
7.4.1 Company Overview 56
7.5 Edwards Lifesciences Corp 57
7.5.1 Company Overview 57
7.6 Vygon SA 57
7.6.1 Company Overview 57
7.7 ICU Medical Inc 57
7.7.1 Company Overview 57
7.8 Kimal plc 57
7.8.1 Company Overview 57
8 Drug Delivery Devices Market Pipeline Products 58
9 Financial Deals Landscape 66
9.1 Debt Offerings 66
9.1.1 Imagion Biosystems to Raise USD0.14 Million in Private Placement of Convertible Notes Due 2026 66
9.2 Equity Offerings 67
9.2.1 AnteoTech to Raise USD2.29 Million in Private Placement of Shares 67
9.2.2 Oncosil Medical to Raise USD4.6 Million in Private Placement of Shares 68
9.2.3 Oncosil Medical Raises USD0.6 Million in Share Purchase Plan (SPP) 70
9.2.4 Gelteq Raises USD5.2 Million in Initial Public Offering (IPO) of Shares 72
9.2.5 Imagion Biosystems to Raise USD0.11 Million in Tranche 1 Private Placement of Shares 73
9.2.6 Imagion Biosystems to Raise USD1.89 Million in Second Tranche Private Placement of Shares 75
9.2.7 Firebrick Pharma to Raise USD1.33 Million in Share Purchase Plan (SPP) 77
9.2.8 Syntara to Raise USD1.76 Million in First Tranche Private Placement of Shares 78
9.2.9 Syntara to Raise USD1.5 Million in Second Tranche Private Placement of Shares 80
9.2.10 Medical Developments International to Raise Approximately USD3.59 Million in Private Placement of Shares 81
10 Recent Developments 82
10.1 Corporate Communications 82
10.1.1 Jan 13, 2025: Saluda Medical secures $100m for Evoke System commercialisation 82
10.2 Financial Announcements 82
10.2.1 Oct 08, 2024: Merit Medical Systems to Announce Third Quarter 2024 Results on October 30, 2024 82
10.2.2 Aug 23, 2024: Mayne Pharma Group Media release for the year ended 30 June 2024 82
10.2.3 Aug 12, 2024: Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update 83
10.2.4 Aug 01, 2024: Merit Medical Systems Announces Q2 2024 Results and Raises Full-Year Guidance 84
10.3 Other Significant Developments 85
10.3.1 Nov 18, 2024: OncoSil Signs Distribution Agreements for Nordics and Egypt 85
10.3.2 May 22, 2024: Starpharma Business Update 85
10.4 Product News 87
10.4.1 Apr 15, 2025: Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom 87
10.4.2 Nov 13, 2024: Needle-Free Influenza Vaccine on the Horizon 87
10.4.3 Nov 01, 2024: Adherium Exhibits at ACAAI Annual Meeting 2024 88
10.4.4 Jun 13, 2024: Acrux Presentation at Hidden Gems in Life Sciences Forum 88
10.5 Research And Development 88
10.5.1 Aug 06, 2024: Gelteq Strengthens Partnership With Monash Innovation Labs 88
10.6 Strategy And Business Planning 89
10.6.1 Aug 06, 2024: Gelteq Strengthens Partnership With Monash Innovation Labs 89
11 Appendix 90
11.1 Research Methodology 91
11.1.1 Coverage 91
11.1.2 Secondary Research 91
11.1.3 Primary Research 92
11.1.4 Market Modeling and Forecasting 93
11.1.5 Company Share Analysis 94
11.1.6 Distribution Share Analysis 94
11.1.7 Benchmarking 95
11.2 GlobalData Consulting 95
11.3 Contact Us 95
11.4 Disclaimer 96